Nateglip M Tablet combines Nateglinide 60 mg and Metformin 500 mg, two complementary oral antidiabetic agents that help regulate blood sugar in patients with type 2 diabetes mellitus. Nateglinide acts as a rapid insulin secretagogue, controlling postprandial glucose spikes, while Metformin improves insulin sensitivity and reduces hepatic glucose output.
This dual-action formulation offers comprehensive glycemic control, making it an essential choice for diabetologists and general practitioners. It is frequently prescribed as a first-line combination therapy for patients who require stronger control than monotherapy can provide.
Nateglip M Tablet belongs to the antidiabetic segment, which maintains strong and steady demand across India. Its proven efficacy, good tolerability, and synergistic effect make it a high-value product for hospitals, clinics, and pharmacies alike.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Nateglip M Tablet ensures consistent business growth. With increasing diabetes prevalence and ongoing prescription support, it provides both medical relevance and commercial reliability in the B2B pharma market.